Nightingale Health Plc
Company release
13 December 2024 at 3:50 p.m. (EET)

Based on Nightingale Health Plc’s option program 2023-ML, 3,600 new Series B shares have been subscribed. As a result of the share subscription approved by Nightingale Health’s Board of Directors on 21 November 2024, the number of Series B shares in the company will increase from 40,293,221 to 40,296,821 shares.

The subscription price of the subscriptions made with the option rights, EUR 9,000, will be entered in the company’s reserve for invested unrestricted equity.

The shares subscribed with option rights were registered in the Trade Register on 13 December 2024. The new shares will establish shareholder rights starting from the registration date.

The shares will be listed on the Nasdaq First North Growth Market Finland marketplace together with the old shares as of December 16, 2024.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

Certified advisor:

Oaklins Finland Ltd, tel. +358 9 6129 670

About Nightingale Health

Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com/